Exscientia Company
Exscientia is applying AI and big data processing to accelerate drug discovery and development. At the forefront of small molecule drug discovery. They are the first company to automate drug design, surpassing conventional human endeavor. Their AI-driven systems actively learn best practice from vast repositories of discovery data and are further enhanced with knowledge acquired from seasoned drug hunters. With better information to hand than any researcher could acquire individually, their knowledge-driven systems design millions of novel, project-specific compounds and pre-assess each for predicted potency, selectivity, ADME and other key criteria. From this, a selection of the best, information-rich compounds are selected for synthesis and assay. With new experimental data generated, the results are integrated and the next design cycle initiated. Rapid design-make-test cycles ensure unparalleled progress towards desired project goals. Exscientia has already delivered exceptional productivity, generating candidates in roughly one-quarter of the time of traditional approaches.
Investors
.png)
.png)
.jpeg)
.png)
.jpeg)
.png)
.png)
(Reupload).png)
(Reupload).png)
.png)
.png)
Technology:
Artificial Intelligence, Biotechnology, Health Care, Pharmaceutical
Industry:
Early Drug Development
Headquarters:
Oxford, Oxfordshire, United Kingdom
Founded Date:
2012-01-01
Employees Number:
101-250
Funding Status:
IPO
Acquisitions Number:
2
Investors Number:
18
Total Funding:
474371987
Estimated Revenue:
$10M to $50M
Last Funding Date:
2022-01-10
Last Funding Type:
Post-IPO Equity
Register and Claim Ownership